Peter Attia quit Ozempic and metformin: what the science says

What did @thebossticks actually say?

The clip is Attia himself explaining why he stopped taking metformin in 2018. His stated reason: he lost confidence in the drug's overall value and, more specifically, found that its "net effect from an exercise perspective standpoint was negative." A second voice then summarizes the takeaway as exercise being more effective than the drug if you can do it efficiently, and Attia confirms that framing.

To be clear, this is not someone making up a claim about Attia. This appears to be Attia speaking in his own words. The creator is essentially amplifying a real position from a well-known physician and longevity podcaster, which changes the fact-check calculus. The question isn't whether Attia said it. The question is whether the underlying claim about metformin and exercise interference is supported by evidence.

Does the science back this up?

Yes, with real caveats. The exercise-metformin interference story has legitimate data behind it, but it is more complicated than "metformin blunts exercise benefits."

The most cited study here is Walton et al. (2019, Nature Aging), which found that older adults taking metformin while doing resistance training showed blunted gains in lean mass and mitochondrial function compared to placebo. That is a real finding. However, a larger trial, the MASTERS trial (Konopka et al., 2019, Aging Cell), found that metformin did not significantly impair aerobic fitness adaptations from endurance training in older adults. So the effect appears to be specific to certain types of training adaptations, not a blanket suppression of exercise benefits.

A 2022 meta-analysis by Malin and Braun in Diabetologia reviewed multiple trials and concluded that metformin modestly attenuates resistance training-induced muscle hypertrophy but does not meaningfully interfere with cardiorespiratory fitness improvements. For someone like Attia, who prioritizes strength and muscle mass for longevity, that distinction matters a lot. His personal risk-benefit calculation is at least defensible given the data.

What did they get wrong (or right)?

Attia gets credit for intellectual honesty here. He did not say metformin is useless or harmful for everyone. He said the negative effects on exercise "were more than enough for me" to stop, and that he is still looking for a "more compelling reason" to take it. That is a personal, context-dependent decision, not a blanket condemnation.

What is missing, and what the creator's summary glosses over, is that Attia is describing a trade-off relevant primarily to people who train hard and prioritize muscle adaptation. For a sedentary person with prediabetes or metabolic syndrome, metformin's glycemic benefits may far outweigh any exercise interference concern. The clip's framing, "exercise is more effective than the drug," is not wrong in the right context, but it could easily mislead someone who is not exercising regularly into concluding they do not need metformin when they might benefit significantly from it.

The mention of Ozempic in the caption is worth flagging. Attia does not appear to say anything about semaglutide in this transcript. That framing in the caption appears to be engagement bait.

What should you actually know?

Metformin is a first-line medication for type 2 diabetes with decades of safety data. The exercise interference concern is real but narrow. It primarily applies to resistance training adaptations, not aerobic fitness, and the effect size is modest. It also appears most relevant in older adults; data in younger populations is thinner.

The decision to stop or start metformin should involve a clinician reviewing your metabolic markers, exercise habits, and overall health goals. Attia's reasoning is coherent for a performance-focused physician who does not have diabetes. It is not a template for patients managing blood sugar disorders to follow without medical guidance.

If you are on metformin and also training seriously, this is a reasonable topic to raise with your prescriber. That is the appropriate response to this kind of evidence, not self-discontinuation.